Thermo Fisher Scientific (TMO) Expected to Announce Earnings on Wednesday

Thermo Fisher Scientific (NYSE:TMO) is expected to be releasing its Q2 2025 earnings data before the market opens on Wednesday, July 23rd. Analysts expect Thermo Fisher Scientific to post earnings of $5.22 per share and revenue of $10.68 billion for the quarter. Thermo Fisher Scientific has set its FY 2025 guidance at 21.760-22.840 EPS.

Thermo Fisher Scientific (NYSE:TMO) last released its quarterly earnings results on Wednesday, April 23rd. The medical research company reported $5.15 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $5.10 by $0.05. The business had revenue of $10.36 billion during the quarter, compared to the consensus estimate of $10.23 billion. Thermo Fisher Scientific had a return on equity of 17.15% and a net margin of 15.19%. The company’s quarterly revenue was up .2% on a year-over-year basis. During the same quarter in the previous year, the business earned $5.11 EPS. On average, analysts expect Thermo Fisher Scientific to post $23 EPS for the current fiscal year and $26 EPS for the next fiscal year.

Thermo Fisher Scientific Price Performance

TMO stock opened at $418.32 on Wednesday. The company has a market capitalization of $157.91 billion, a P/E ratio of 24.53, a price-to-earnings-growth ratio of 2.26 and a beta of 0.77. The company has a debt-to-equity ratio of 0.64, a quick ratio of 1.38 and a current ratio of 1.77. Thermo Fisher Scientific has a 52-week low of $385.46 and a 52-week high of $627.88. The business has a 50-day simple moving average of $409.67 and a two-hundred day simple moving average of $474.77.

Thermo Fisher Scientific Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Wednesday, October 15th. Shareholders of record on Monday, September 15th will be paid a dividend of $0.43 per share. The ex-dividend date of this dividend is Monday, September 15th. This represents a $1.72 dividend on an annualized basis and a yield of 0.41%. Thermo Fisher Scientific’s dividend payout ratio (DPR) is currently 10.09%.

Insider Buying and Selling at Thermo Fisher Scientific

In other news, EVP Gianluca Pettiti sold 300 shares of the company’s stock in a transaction on Monday, April 28th. The shares were sold at an average price of $429.93, for a total value of $128,979.00. Following the transaction, the executive vice president owned 23,167 shares of the company’s stock, valued at approximately $9,960,188.31. This represents a 1.28% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Insiders own 0.33% of the company’s stock.

Institutional Inflows and Outflows

An institutional investor recently raised its position in Thermo Fisher Scientific stock. Revolve Wealth Partners LLC raised its holdings in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) by 4.2% in the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 491 shares of the medical research company’s stock after buying an additional 20 shares during the period. Revolve Wealth Partners LLC’s holdings in Thermo Fisher Scientific were worth $255,000 at the end of the most recent reporting period. Hedge funds and other institutional investors own 89.23% of the company’s stock.

Analysts Set New Price Targets

A number of equities analysts have recently weighed in on TMO shares. Stifel Nicolaus cut their target price on Thermo Fisher Scientific from $665.00 to $620.00 and set a “buy” rating on the stock in a research note on Thursday, April 24th. Wall Street Zen upgraded Thermo Fisher Scientific from a “hold” rating to a “buy” rating in a research note on Wednesday, May 21st. Royal Bank Of Canada cut their target price on Thermo Fisher Scientific from $651.00 to $637.00 and set an “outperform” rating on the stock in a research note on Thursday, April 24th. Scotiabank upgraded Thermo Fisher Scientific from a “sector perform” rating to a “sector outperform” rating and set a $590.00 target price on the stock in a research note on Friday, July 11th. Finally, Barclays cut their target price on Thermo Fisher Scientific from $475.00 to $450.00 and set an “equal weight” rating on the stock in a research note on Tuesday, June 24th. Four research analysts have rated the stock with a hold rating and seventeen have given a buy rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $600.30.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.